Placebo responses in randomized trials of antiepileptic drugs

Epilepsy and Behavior

Volumn 17, Issue 1, 2010, Pages 64-69

  Guekht, A B ^a   Korczyn, A D ^b   Bondareva, I B ^c   Gusev, E I ^a  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b TEL AVIV UNIVERSITY   (Israel)

^c FEDERAL RESEARCH AND CLINICAL CENTER OF PHYSICAL CHEMICAL MEDICINE OF FEDERAL MEDICAL BIOLOGICAL AGENCY   (Russian Federation)

Author keywords

Epilepsy; Meta analysis; Placebo effect

Indexed keywords

ANTICONVULSIVE AGENT; ESLICARBAZEPINE ACETATE; ETIRACETAM; HARKOSERIDE; LOSIGAMONE; PLACEBO; PREGABALIN; REMACEMIDE; RETIGABINE; TIAGABINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; FOCAL EPILEPSY; HUMAN; META ANALYSIS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTICONVULSANTS; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; EPILEPSY; FEMALE; HUMANS; MALE; MEDLINE; ODDS RATIO; PLACEBO EFFECT; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 72949099860     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2009.10.007     Document Type: Article

References (42)

1. Dorn S.D., Kaptchuk T.J., Park J.B., et al. A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol Motil 19 (2007) 630-637
2. Macedo A., Baños J.E., and Farré M. Placebo response in the prophylaxis of migraine: a meta-analysis. Eur J Pain 12 (2008) 68-75
3. De Craen A.J., Tijssen J.G., de Gans J., and Kleijnen J. Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J Neurol 247 (2000) 183-188
4. Korczyn A.D. Placebos and other biases in clinical trials in dementia. In: Canal N., et al. (Ed). Guidelines for drug trials in memory disorders (1993), Raven Press, New York 135-141
5. Stolk P., Ten Berg M.J., Hemels M.E., and Einarson T.R. Meta-analysis of placebo rates in major depressive disorder trials. Ann Pharmacother 37 (2003) 1891-1899
6. Sonawalla S.B., and Rosenbaum J.F. Placebo response in depression. Dialogues Clin Neurosci l 4 (2002) 105-113
7. De la Fuente-Fernandez R., Ruth T.J., Sossi V., et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293 (2001) 1164-1166
8. Shetty N., Friedman J.H., Kieburtz K., Marshall F.J., Oakes D., and for the Parkinson Study Group. The placebo response in Parkinson's disease. Clin Neuropharmacol 22 (1999) 207-212
9. Hróbjartsson A., and Gøtzsche P.C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344 (2001) 1594-1602
10. Burneo J.G., Montori V.M., and Faught E. Magnitude of the placebo effect in randomized trials of antiepileptic agents. Epilepsy Behav 3 (2002) 532-534
11. Rheims S., Cucherat M., Arzimanoglou A., and Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug resistant partial epilepsy. PLoS Med 5 (2008) 1223-1236
12. Niklson I., Edrich P., and Verdru P. Identifying baseline characteristics of placebo responders versus nonresponders in randomized double-blind trials of refractory partial-onset seizures. Epileptic Disord 8 (2006) 37-44
13. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the Quorom Statement. Lancet 354 (1999) 1896-1900
14. Egger G.D., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 315 (1997) 629-634
15. Thompson S.G. Systematic review: why sources of heterogeneity in meta-analysis should be investigated. Br Med J 309 (1994) 1351-1355
16. Sharief M., Viteri C., Ben-Menachem E., et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 25 (1996) 217-224
17. Privitera M., Fincham R., Penry J., et al., for the Topiramate YE Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 46 (1996) 1678-1683
18. French J.A., Mosier M., Walker S., Sommerville K., Sussman N., and for the Vigabatrin Protocol 024 Investigative Cohort. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 46 (1996) 54-61
19. Ben-Menachem E., Henriksen O., Dam M., et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 37 (1996) 539-543
20. Faught E., Wilder B.J., Ramsay R.E., et al., for the Topiramate YD Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 46 (1996) 1684-1690
21. Tassinari C.A., Michelucci R., Chauvel P., et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 37 (1996) 763-768
22. Kalviainen R., Brodie M.J., Duncan J., et al., for the Northern European Tiagabine Study Group. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Epilepsy Res 30 (1998) 31-40
23. Dean C., Mosier M., and Penry K. Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 40 (1999) 74-82
24. Shorvon S.D., Lowenthal A., Janz D., Bielen E., Loiseau P., and for the European Levetiracetam Study Group. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41 (2000) 1179-1186
25. Cereghino J.J., Biton V., Abou-Khalil B., et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
26. Bruni J., Guberman A., Vachon L., Desforges C., and for the Canadian Vigabatrin Study Group. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. Seizure 9 (2000) 224-232
27. Yen D.J., Yu H.Y., Guo Y.C., et al. A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia 41 (2000) 1162-1166
28. Faught E., Ayala R., Montouris G.G., Leppik I.E., and for the Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 57 (2001) 1774-1779
29. Bauer J., Dienel A., Elger C.E., and for the Losigamone Study Group. Losigamone add-on therapy in partial epilepsy: a placebo-controlled study. Acta Neurol Scand 103 (2001) 226-230
30. Guberman A., Neto W., Gassmann-Mayer C., and for the EPAJ-119 Study Group. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 106 (2002) 183-189
31. Chadwick D.W., Betts T.A., Boddie H.G., et al. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen. Seizure 11 (2002) 114-123
32. Jones M.W., Blume W.T., Guberman A., et al. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 800 mg/day) in a B.I.D. regimen. Seizure 11 (2002) 104-113
33. Baulac M., Klement S., and for the Losigamone Study Group. Efficacy and safety of losigamone in partial seizures: a randomized double-blind study. Epilepsy Res 55 (2003) 177-189
34. Arroyo S., Anhut H., Kugler A.R., Lee C.M., et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45 (2004) 20-27
35. Sackellares J.C., Ramsay R.E., Wilder B.J., Browne III T.R., and Shellenberger M.K. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 45 (2004) 610-617
36. Brodie M.J., Duncan R., Vespignani H., et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 46 (2005) 31-41
37. Elger C.E., Brodie M.J., Anhut H., Lee C.M., and Barrett J.A. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 46 (2005) 1926-1936
38. Beydoun A., Uthman B.M., Kugler A.R., et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 64 (2005) 475-480
39. Tsai J.J., Yen D.J., Hsih M.S., et al. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia 47 (2006) 72-81
40. Ben-Menachem E., Biton V., Jatuzis D., et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48 (2007) 1308-1317
41. Porter R.J., Partiot A., Sachdeo R., Nohria V., Alves W.M., and for the 205 Study Group. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 68 (2007) 1197-1204
42. Elger C., Bialer M., Cramer J.A., et al. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 48 (2007) 497-504